The huge wealth of biomedical information that is currently available is underused because of the difficulties in seeking, integrating and analyzing the relevant information. There is also a great difficulty for the identification and use of clinically actionable information.
The main goal of this group, led by Laura I. Furlong and Ferran Sanz, is to develop computational approaches that enables a better understanding of disease mechanisms and the mode of action of drugs. We approach this challenge from different perspectives, including:
The group is currently coordinating a large scale scientific initiative, the IMI project eTRANSAFE: Enhancing Translational Safety Assessment through Integrative Knowledge Management, which aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process.
The group is also partner in other EU-funded projects, like the ongoing IMI projects:
And the ongoing H2020 projects:
Other examples of recent european projects participated or coordinated by the IBI group are iPiE, EMIF, MedBioinformatics, ELIXIR-EXCELERATE, eTOX, OpenPHACTS, INBIOMEDvision, VPH NOE, EU-ADR, @neurIST and CancerGRID.
In February 2020 some members of the group created the spin off MedBioinformatics Solutions, which aims to exploit biomedical data to support drug discovery pipelines and to enhance biomedical research.